Standard treatment for girls with labial fusion has included topical estrogen cream, manual separation, or surgery. Side effects may limit the use of topical estrogen. Betamethasone has recently shown efficacy at separating labial fusion. Local irritation and inflammation may be an initiator of labial fusion. No adverse effects of betamethasone treatment have been documented. Long-term side effects are unknown. This study compares therapies for conservative management of labial fusion for efficacy and focuses on the response rate, time to separation, recurrence, and side effects of treatment.
A retrospective chart review.
One hundred fifty-one prepubertal girls, mean age 3 years (range 0.25-8.75 years) diagnosed with labial fusion.
Main Outcome Measures
To investigate the incidence of related symptoms, length of topical estrogen or betamethasone treatment, side effects, rate of successful separation, rates of recurrence, percentage requiring surgery, and postoperative outcomes in patients with labial adhesion who underwent treatment.
Of 151 patients with labial adhesion, 11 (7.3%) presented with urinary frequency, 30 (19.9%) with urinary tract infections, 13 (8.6%) with vaginitis, and 19 (12.6%) with post-void dripping. When compared to patients treated with betamethasone (1.3 months), patients treated primarily with premarin took nearly twice as long (2.2 months) for resolution of their adhesions. Rates of recurrence were lower for patients receiving betamethasone therapy. Side effects for estrogen therapy included breast budding and vaginal bleeding, and for betamethasone, local irritation was reported. Some patients went on to surgery and experienced recurrence after surgery.
Initial comparison of topical estrogen and betamethasone treatment of labial fusion suggests that betamethasone may separate fusion quicker with less recurrence and fewer side effects than topical estrogen therapy.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Pediatric and Adolescent Gynecology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Adhesions of the labia minora. A study of 50 patients.Obstet Gynecol. 1972; 39: 65
- Prepubertal labial adhesions: evaluation of a referral population.Am J Obstet Gynecol. 2002; 187: 327
- Appearance of the hymen in prepubertal girls.Pediatrics. 1992; 89: 387
Sanfilippo JS. Vulvovaginitis. In: Nelson Textbook of Pediatrics (15th ed.). Edited by WE Nelson, RE Behrman, RM Kliegman, et al, Philadelphia, WB Saunders, 1996, p 1555.
- Labial adhesions in a girl with isolated premature thelarche: the importance of estrogenization.J Pediatr Adolesc Gynecol. 2003; 16: 31
- Serum estradiol levels in infants with and without labial adhesions: the role of estrogen in the etiology and treatment.Pediatr Dermatol. 2007; 24: 373
- Estrogen affects the cellular metabolism of the anterior cruciate ligament. A potential explanation for female athletic injury.Am J Sports Med. 1997; 25: 704
- Betamethasone cream for the treatment of pre-pubertal labial adhesions.J Pediatr Adolesc Gynecol. 2006; 19: 407
- Treatment of prepubertal girls with labial adhesions.J Pediatr Adolesc Gynecol. 1999; 12: 67
- Pro-conservative management for asymptomatic labial adhesions in the prepubertal child.J Pediatr Adolesc Gynecol. 2000; 13: 183
- Is the topical application of oestrogen cream an effective intervention in girls suffering from labial adhesions?.Arch Dis Child. 2007; 92: 268
- Topical estrogen therapy in labial adhesions in children: therapeutic or prophylactic?.J Pediatr Adolesc Gynecol. 2007; 20: 241
- The modulation of aromatase and estrogen receptor alpha in cultured human dermal papilla cells by dexamethasone: a novel mechanism for selective action of estrogen via estrogen receptor beta?.J Invest Dermatol. 2006; 126: 2010
© 2009 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.